On July 10, after issuing a warning that the firm would expect higher than usual profits, BIOS jumped >20% that friday. Then, once its quarterly earnings were released, it was clear the company had not tricked us: + 25.8% REVENUES OF 14.3 MILLION IN THE FIRST SEMESTER, +44.2% to 5.5 million euros in Plant extracts business line, probiotics business registered a...
Biosearch is clearly improving its fundamental results but investors may not like that drop on EBITDA. That is why we could expect Biosearch go towards 0.50 Fib level at 0.876 and bounce back to 1.07 level, with the risk of losing 10% once the stock is bought at 0.876. So short the firm in the next 15 days, and long until you feel comfortable. It may also be a...
